25 results match your criteria: "UCL Louvain Medical School[Affiliation]"
Clin Microbiol Infect
November 2024
Unit of Mycology, Statens Serum Institut, Copenhagen, Denmark; Department of Clinical Microbiology, University Hospital Rigshospitalet, Copenhagen, Denmark.
Objectives: A post hoc analysis used pooled STRIVE/ReSTORE trial data to determine outcomes with rezafungin versus caspofungin by Candida species and antifungal susceptibility.
Methods: The efficacy and safety of once weekly rezafungin 400/200 mg versus once daily caspofungin 70/50 mg was demonstrated in the randomized, double-blind phase 2 STRIVE (NCT02734862) and phase 3 ReSTORE (NCT03667690) trials involving adults with candidaemia and/or invasive candidiasis. In this analysis, data were pooled for patients with a documented Candida infection within 96 hours of randomization who also received ≥1 dose of study drug.
Crit Care
November 2024
Division of Infectious Diseases, Department of Internal Medicine, and Department of Medical Microbiology and Immunology, University of California Davis Medical Center, Sacramento, CA, USA.
Background: Invasive candidiasis/candidemia (IC/C) is associated with a substantial health economic burden driven primarily by prolonged hospital stay. The once-weekly IV echinocandin, rezafungin acetate, has demonstrated non-inferiority to caspofungin in the treatment of IC/C. This paper reports a post hoc pooled exploratory analysis of length of stay (LoS) for hospital and intensive care unit (ICU) stays in two previously published clinical trials (ReSTORE [NCT03667690] and STRIVE [NCT02734862], that compared rezafungin with daily IV caspofungin (stable patients in the caspofungin group who met relevant criteria could step down to fluconazole after 3 days or more).
View Article and Find Full Text PDFAnn Transl Med
October 2024
ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
Ann Transl Med
October 2024
ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
Ann Transl Med
October 2024
ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
Ann Transl Med
October 2024
ICU Department, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
Crit Care
October 2024
Médecine Intensive Réanimation, Inserm U1285, CNRS, UMR 8576-UGSF-Unité de Glycobiologie Structurale et Fonctionnelle, CHU de Lille, Université de Lille, Lille, France.
Background: Rezafungin is an echinocandin approved in the US and EU to treat candidaemia and/or invasive candidiasis. This post-hoc, pooled analysis of the Phase 2 STRIVE and Phase 3 ReSTORE trials assessed rezafungin versus caspofungin in patients with candidaemia and/or invasive candidiasis (IC) in the intensive care unit (ICU) at randomisation.
Methods: STRIVE and ReSTORE were randomised double-blind trials in adults with systemic signs and mycological confirmation of candidaemia and/or IC in blood or a normally sterile site ≤ 96 h before randomisation.
Crit Care Med
August 2024
CHIREC, Université Libre de Bruxelles, Brussels, Belgium.
Clin Infect Dis
September 2024
University of California Davis Medical Center, Sacramento, California, USA.
Crit Care Med
January 2024
Department of Intensive Care, CHU UCL Namur Godinne, UCL Louvain Medical School, Campus Godinne, Godinne, Belgium.
Lancet Infect Dis
March 2024
Division of Infectious Diseases, Department of Internal Medicine, University of Alabama at Birmingham, Birmingham, AL, USA.
Ann Transl Med
October 2023
ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
Front Immunol
November 2023
Nephrology and Kidney Transplantation Unit, Department of Translational Medicine (DIMET), University of Piemonte Orientale (UPO), "Maggiore della Carità" University Hospital, Novara, Italy.
Crit Care Med
November 2023
ICU Brugmann University Hospital, ULB University, Brussels, Belgium.
Crit Care Med
October 2023
ICU, Brugmann University Hospital, ULB University, Brussels, Belgium.
Ann Transl Med
August 2023
ICU, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
Crit Care Med
August 2023
ICU Brugmann University Hospital, ULB University, Brussels, Belgium.
Saudi J Anaesth
March 2023
Department of Intensive Care, CHU UCL Godinne Namur, UCL Louvain Medical School, Yvoir, Belgium.
The optimization of patients' treatment in the intensive care unit (ICU) needs a lot of information and literature analysis. Many changes have been made in the last years to help evaluate sedated patients by scores to help take care of them. Patients were completely sedated and had continuous intravenous analgesia and neuromuscular blockades.
View Article and Find Full Text PDFJ Antimicrob Chemother
July 2023
Radboudumc-CWZ Center of Expertise for Mycology, Nijmegen, the Netherlands.
Front Immunol
March 2023
Intensive Care Unit (ICU) Department, Université Catholique de Louvain (UCL) Louvain Medical School, Centre Hospitalier Universitaire (CHU) UCL Godinne Namur, Yvoir, Belgium.
Curr Opin Clin Nutr Metab Care
March 2023
Department of Intensive Care, Brugmann University Hospital, Université Libre de Bruxelles (ULB), Brussels, Belgium.
Purpose Of Review: Hyperammonaemia is almost always develops in patients with severe liver failure and this remains the commonest cause of elevated ammonia concentrations in the ICU. Nonhepatic hyperammonaemia in ICU presents diagnostic and management challenges for treating clinicians. Nutritional and metabolic factors play an important role in the cause and management of these complex disorders.
View Article and Find Full Text PDFCrit Care
February 2023
ICU Brugmann University Hospital, ULB University, Brussels, Belgium.
Crit Care Med
February 2023
ICU Department, Centre Hospitalier Universitaire Brugmann, Brussels, Belgium.
Expert Opin Emerg Drugs
December 2022
Intensive Care Department, Brugmann University Hospital, Brussels, Belgium.
Introduction: Invasive candidiasis or candidemia is a severe infection affecting more than 250,000 people worldwide every year. It is present in up to 16% of ICU patients. The prognosis of these infections is unfavorable, with global death estimated around 50,000 per year, which corresponds to up to 40% depending on patient severity and comorbidities.
View Article and Find Full Text PDF